An interventional study of Lifestyle Kit in Metabolic Dysfunction-associated Steatotic Liver Disease, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Stanford University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the world. It is estimated that 38% of American children with obesity have steatotic liver disease. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. This study intends to provide insight to barriers of recommended care for pediatric patients with Hispanic ethnicity and a new diagnosis of MASLD. The investigators propose to augment existing structural barriers related to health literacy, food accessibility and dietary knowledge, and access to safe physical activity through a healthy lifestyle toolkit and individualized nutritional counseling.
The Hispanic population represents the largest and fastest growing ethnic group in the United States. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. An adult meta-analysis found a prevalence rate of 22.9% among individuals of Hispanic ethnicity. A pediatric retrospective study found that children who are Hispanic are 5 times more likely to have MASLD than their age/gender matched peers who identify as black. The etiology of why individuals of Hispanic ethnicity are at higher risk of developing MASLD, and subsequently associated co-morbidities such as insulin resistance, diabetes, and cardiovascular disease, is thought to be multifactorial. There is evidence to suggest that individuals of Hispanic ethnicity have a genetic predisposition for hepatic fat infiltration.11 Additionally, it has been postulated that social determinants of health, such as economic stability and health care access and quality contribute to an increased risk.
The American Association for the Study of Liver Diseases (AASLD) recommends lifestyle modification as the foundation of treatment for MASLD. Implementing dietary changes and increasing physical activity contribute to weight loss, which has been found to reduce hepatic steatosis. A 7-10% weight loss can improve histopathological features of MASLD, including fibrosis.Application of dietary modification, such as adherence to the Mediterranean dietary pattern, can decrease hepatic fat content, even in the absence of weight loss.Though lifestyle intervention has been found to be effective, barriers to implementation exist. In a study of adult patients of Hispanic ethnicity with a diagnosis of MASLD, access to nutritious food and a safe exercising environment limited the ability to follow through with recommended lifestyle changes.A survey study of pediatric patients with MASLD found that many lacked the opportunity for physical activity, though the majority expressed an interest in participation.16 Health literacy, or the ability to obtain and comprehend medical information, has also been found to be a barrier to effective care. In a qualitative interview study of adults with MASLD, health literacy was hindered by the availability of liver disease resources in the patient's preferred language. There is limited pediatric data regarding perceived barriers to implementing lifestyle changes. With this study, the investigators hope to minimize some of the social determinants of health that can impact Hispanic pediatric MASLD patients and help them participate in the recommended standard of care.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a healthy lifestyle kit and be asked interview questions about its efficacy.
Other: Lifestyle Kit
The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.
Number of Social Determinants of Health Impacting Participants
Social Determinants of Health Screener will identify the presence of food, housing, and/or transportation insecurity.
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Mean Change from Baseline AST at 3 or 6 month follow-up appointment
AST lab value
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Mean Change from Baseline ALT at 3 or 6 month follow-up appointment
ALT Lab value
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Mean Change from Baseline GGT at 3 or 6 month follow-up appointment
GGT Lab value
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Mean BMI Change from Baseline at 3 or 6 month follow-up appointment
BMI
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Mean Weight Change from Baseline at 3 or 6 month follow-up appointment
weight
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Socioeconomic status of Participants participating in the study
Socioeconomic status
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Ethnic background of Participants participating in the study
ethnic background
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Primary language of Participants participating in the study
primary language
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Plan to share: No — There currently are no plans to share IPD.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jul 2025 → Apr 2026, primary completion Jul 2026 → Jul 2028 and completion Jul 2027 → Jul 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.